Two years after local emir Djibril Diallo fled his home in northern Burkina Faso following death threats from Islamist militants, he received an unexpected request: to return and take part in peace talks with the same people who wanted him dead.
Ryvu Therapeutics (WSE:RVU) today announced the online publication of two posters and an oral presentation demonstrating clinical and pre-clinical activity of its selective CDK8/19 inhibitor RVU120 (previously SEL120) and the dual PIM/FLT3 inhibitor SEL24 (MEN1703), in-licensed by Menarini Group from Ryvu Therapeutics, at the Annual European Hematology Association (EHA) 2021 Virtual Congress.
Robust signals of clinical efficacy, with ORR of 83%, of which 67% are CR/CRiFive patients with responses longer than 1 yearLongest remission 858 days, still ongoingRapid onset of responses (TTR 29 days)Iadademstat and azacitidine combination shows a good safety profile MADRID, Spain and CAMBRIDGE, Mass., June 11, 2021 (GLOBE NEWSWIRE) Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with s